Effect of AF, olaparib and aurola treatment on immune-related

Concurrent schedule of olaparib and ICB is the most efficacious in a

Laurie FREIRE BOULLOSA, PhD Student

The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a

Histologic transformation in lung cancer: when one door shuts, another opens - Yuki Sato, Go Saito, Daichi Fujimoto, 2022

PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to

Signal pathways and precision therapy of small-cell lung cancer

Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review - ScienceDirect

ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment - ScienceDirect